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Abstract
Background: Polymorphic variants and mutations disrupting canonical splicing isoforms are among the
leading causes of human hereditary disorders. While there is a substantial evidence of aberrant splicing
causing Mendelian diseases, the implication of such events in multi-genic disorders is yet to be well
understood. We have developed a new tool (SpliceScan II) for predicting the effects of genetic
variants on splicing and cis-regulatory elements. The novel Bayesian non-canonical 5’GC splice site (SS)
sensor used in our tool allows inference on non-canonical exons.
Result: Our tool performed favorably when compared with the existing methods in the context of genes
linked to the Autism Spectrum Disorder (ASD). SpliceScan II was able to predict more aberrant
splicing isoforms triggered by the mutations, as documented in DBASS5 and DBASS3 aberrant splicing
databases, than other existing methods. Detrimental effects behind some of the polymorphic variations
previously associated with Alzheimer’s and breast cancer could be explained by changes in predicted
splicing patterns.
Conclusions: We have developed SpliceScan II, an effective and sensitive tool for predicting the
detrimental effects of genomic variants on splicing leading to Mendelian and complex hereditary
disorders. The method could potentially be used to screen resequenced patient DNA to identify de novo
mutations and polymorphic variants that could contribute to a genetic disorder.
Background
Human pre-mRNA sequences are subjected to complex multi-stage modifications by splicing, where
frequent variations in this process contribute to the proteome diversity. During splicing the intronic
sequences are recognized and excised by the spliceosome, where the relatively short exonic sequences
are joined together to form mature mRNA. The Splice Site (SS) signals at the intronic 5’ end (donor) and
3’ end (acceptor, polypyrimidine tract and the branch point) are necessary, but not sufficient for accurate
and efficient exon recognition by the spliceosome [1-2]. Additional exon-proximal elements are required
for proper recognition of weakly defined or alternatively committed exons [3]. These cis-acting elements
include a repertoire of Exonic Splicing Enhancers (ESEs) and Intronic Splicing Enhancers (ISEs) along
with a number of Exonic Splicing Silencers (ESSs) and Intronic Splicing Silencers (ISSs). The
evolutionary fine-tuned antagonism between enhancing and silencing elements leads to the proper
splicing of human pre-mRNAs. Mutations disrupting cis-acting elements and SSs themselves, as well as
mutations creating cryptic SSs and cis-acting factor binding sites can lead to severe diseases [4].
Mutations affecting alternative and constitutive splicing play a major role in human hereditary disorders
[5]. More than 5,477 splicing mutations (as of July 2008) have been documented in the HGMD database
[6], which makes this group of mutations one of the most frequent disease-causing alterations. Databases
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DBASS5 [7] and DBASS3 [8] contain 431 and 283 well annotated disease-causing aberrant splicing
events, respectively. A clear understanding of elements affecting splicing could potentially aid diagnosis
and development of novel therapeutic strategies [9-10].
Since alternations in splicing are ubiquitous among human multi-exonic genes [11], it is important to
understand the key regulators of this process. The 5’GC SSs, flanking <1% of human exons [12], were
shown to play an important role in the genesis of alternative splicing in human genes [13] and were
found to accumulate in mammalian lineage [14]. The majority of 5’GC SS sensors, i.e. computational
procedures reporting how well an oligonucleotide would play a role of a SS, built up to date is based on
weight matrices [12, 15]. Being an elusive signal, it is difficult to collect a representative learning set that
would facilitate building a stronger model. The importance of proper modeling the 5’GC SS comes from
the observation that some mutations documented in DBASS5 [7], such as IVS27+3_6dup(GGGT)(-96),
IVS7+1G>T(-40), IVS9+1G>A(-45) and others trigger use of cryptic non-canonical 5’GC SS. Despite
of the importance of this splicing signal only few splicing prediction methods, such as GeneSequer [16]
and NetGene2 [17], are able to score non-canonical exons.
Human introns contain many decoy exons that are similar to authentic exons, but are never committed by
the spliceosome and outnumber the real exons by an order of magnitude [18]. The mechanisms that
allow accurate discrimination between decoy exons and their authentic counterparts are poorly
understood. Codon sequence contained in coding exons have particular 3-periodic compositional biases
[19] that allow gene finders, such as GenScan [20] and HMMgene [21], stitching putative coding exons
in a frame-consistent fashion with high accuracy [22]. However, methods that rely on protein coding
potential features experience severe performance loss when confronted with non-coding exons [23-24].
On the other hand, human mutations frequently create de novo cryptic exons with no apparent coding
potential leading to severe disorders caused by aberrant splicing [7-8]. Therefore, tools are needed to
explain the effects of mutations in terms of signals associated with splicing free of protein coding context
[3].
Investigation whether prediction of SSs could be accomplished without relying on protein coding
potential started with simple tools such as SpliceView [25] and GENIO [26]. The NetUTR [24] tool
has been specifically constructed to predict SSs in 5’ untranslated regions (UTRs), therefore addressing
the problem of splicing prediction without relying on protein coding features. Maximum Entropy Sensor
[27] has been found to be one of the most sensitive diagnostic methods predicting the effects of
mutations in human genes [7-8, 28]. ExonScan [29], a tool built around the exon definition model,
combines the power of the Maximum Entropy Sensor with the Logarithm of Odds (LOD) biases
associated with the previously reported ESEs [30], ESSs [29] and poly-G runs (known ISEs [31]).
Recent CRYP-SKIP [32-33] tool is based on multivariate logistic discrimination procedure that
distinguishes the two aberrant splicing outcomes from DNA sequences. Bayesian SS sensor [23], shown
to outperform the Maximum Entropy Sensor [34], is an integral part of the SpliceScan tool [23], built
around the SS definition model supported by the enhancers predicted with the MHMMotif tool [23] and
various other previously reported silencing and enhancing signals. The SpliceScan has been found to
be especially efficient on the test set of short 5’ UTR fragments.
We introduce a new tool SpliceScan II built around the exon definition model [1]. Unlike in
previous SpliceScan [23] method, the new tool has option of displaying factors contributing to a
score assigned to a specific exon isoform thus informing medical practitioners of possible changes in
splicing commitment caused by polymorphic variants and mutations. We have used a much larger set of
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orthologous exons originating from 23 Tetrapoda organisms to train the new splicing model following
an observation that the spliceosomal and cis-acting factors stay mostly intact across vertebrates [4, 35-
38], where the genes encoding well-known RNA binding proteins involved in splicing regulation are
enriched with ultraconserved elements [39]. The SpliceScan II tool is based on the Bayesian SS
sensors, and uses the novel set of enhancer and silencer elements computationally predicted in Tetrapoda
organisms [40]. Having a large collection of Tetrapoda orthologous exons we were able to collect
learning set of 5’GC SSs, representative enough to train a new Bayesian 5’GC SS sensor, used in our
tool. We compared the performance of our tool with other methods on gene fragments annotated in
DBASS5 [7] and DBASS3 [8] and gene structures linked to Autism Spectrum Disorder (ASD). We
further evaluated the method by predicting the effects on splicing for some of the previously reported
polymorphisms associated with Alzheimer’s and the Breast cancer, suggesting possible mechanism
causing the disease predisposition associated with such variants.
Results and Discussion
Predicting aberrant splicing isoforms
As a first step, we predicted the effects of mutations on splicing. Figure 1 shows an example of
SpliceScan II predicted aberrant splicing events induced by the IVS2+2delC mutation causing
familial arterial hypertension as annotated in DBASS5 [7]. Table 1 shows prediction accuracies achieved
by ExonScan [29], GenScan [20] and SpliceScan II in context of the gene fragments annotated
in aberrant splicing databases [see Additional File 1]. For a prediction to be scored as correct a tool
should predict the exonic boundary change the way it is annotated in the databases, i.e. the original
exonic boundary and an aberrant boundary resulting from a mutation. In case of mutation creating a
cryptic exon, appearance of both 3’ and 5’ boundaries of a cryptic exon have to be predicted correct. We
compared only the methods that predict a gene structure in terms of exons, i.e. predicting which
particular exon isoform is preferentially used in as result of mutation.
Our tool was twice as accurate compared to other top performing methods for gene splicing prediction,
such as GenScan [20]. This result clearly demonstrates the performance improvement on gene
fragments containing aberrant splicing isoforms when a method relies on splicing factors and signals
rather than protein coding potential. The other ExonScan [29] method was not able to predict many
aberrant splicing isoforms mainly because of the limited sensitivity, as discussed in the following
subsection.
SpliceScan II splicing prediction accuracy
We estimated the performance of various ab initio splicing prediction methods with our web-based
testing framework [34] using the test set [see Subsection Constructing the test set] as a benchmark. The
comparative performance of the SpliceScan II is shown in Figure 2. The comparative performance
of the 5’GC SS sensor on the set of gene structures containing 1,320 5’GC SSs [see Subsection Learning
the model] is shown in Figure 3. In these experiments Sensitivity (Sn) and Specificity (Sp) were
calculated according to the formulas
AE
TESn = ,
PE
TESp = ,
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where TE is the number of accurately predicted exon boundaries, AE is the number of annotated exon
boundaries in the test set and PE is the number of predicted exon boundaries.
The winning tool should be both sensitive and specific when predicting exonic boundaries for various
thresholds. Our tool appeared to be twice as sensitive compared to other similar NetUTR [24] and
ExonScan [29] methods (although at expense of much lower specificity), which would allow scoring
roughly twice as many exonic isoforms. It has lesser sensitivity than the previously constructed
SpliceScan [23] method, but the objective of two methods is different. Our new tool has the main
focus to predict how certain internal exonic isoforms get activated, rather than assigning probabilistic
scores to all putative SSs the way SpliceScan [23] and NetUTR [24] do.
Characteristics of tools shown in Figure 2 emphasize on comparative aspect of their performance, and do
not necessarily reflect the prediction quality in practical cases. Intronic regions in our test set are long,
which negatively affects sensitivity vs. false positive rates (the majority of false positive exons is
predicted within introns). It has also been a split-sample test design for our tool, where we specifically
removed the extended exons associated with the test set from the learning set, which has slightly
detrimental effect on the SpliceScan II performance. The mutations causing aberrant splicing
events, as annotated in DBASS databases [7-8], are normally located close to annotated exons, therefore
in real experiments area of focus would normally be shifted to an annotated exon and surrounding
context, where performance of our and other methods would certainly be higher than shown in Figure 2.
The 5’GC SS sensor outperforms the existing sensor designs based on weight matrices [12, 15] for
sensitivity values higher than 35%. The initial artifact in the trajectory below 35% sensitivity could be
explained by the fact that 34.15% of 5’GC SSs are CAGGCAAGT and AAGGCAAGT, on which our
sensor returns two predefined normalized scores of 0.914 and 0.744, correspondingly.
Predicting variations in splicing induced by disease associated
SNPs
We have predicted number of changes in gene splicing patterns induced by the polymorphic variations
previously associated with predisposition to the breast cancer and Alzheimer’s as shown in [see
Additional File 2 Tables S1 and S2]. Some of the predicted changes are quite dramatic, but in general
SNPs cause milder effect compared to the effect of mutations [see Section Predicting aberrant splicing
isoforms] where annotated SSs routinely disappear or mutations create new cryptic exons. Number of
polymorphic variants, potentially alternating composition of gene isoforms, was predicted for the disease
associated and randomly selected groups of control SNPs are shown in Table 2.
Here we tried to rank the polymorphic variations according to their possible destabilizing effect on
splicing. We reported [see Additional File 2 Tables S1 and S2] polymorphic variations that change
annotated exon score more than 2%, which according to [41] could cause increased exon skipping or
retention compared to the reference exon. According to Table 2 number of such events induced by the
disease associated SNPs is at least 3.5 times higher compared to control SNP groups, which suggests
active role of the disease associated SNPs in modulation of predicted exonic strengths. These variations
could indicate consequently different splicing commitment patterns for the affected exonic isoforms.
Another class of events is the score change for the exons overlapping with the annotated exon, which
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according to [7-8, 41] could disrupt mRNA inclusion patterns for alternatively used exon isoforms
sharing an annotated boundary. According to Table 2 number of such events induced by the disease
associated SNPs is also significantly increased compared to control SNP groups, which suggests
destabilizing role for many of such changes listed in [see Additional File 2 Tables S1 and S2]. Similar
splicing destabilizing effect could be achieved by simply removing or creating additional exon isoforms
sharing a SS with an annotated exon and the number of such predicted events induced by the disease
associated SNPs is also substantially increased compared to controls. On the contrary, the number of
polymorphic variations associated with creation of new cryptic SSs or pseudo exon deletion is
approximately the same for the disease associated and control group of SNPs, which suggests
insignificant effect on splicing for these classes of events.
Conclusions
Using the set of previously predicted cis-acting elements we were able to construct a splicing simulator
capable of predicting exon score changes induced by mutations and polymorphic variants thus
elucidating possible mechanism behind such variants leading to disorders caused by aberrant splicing.
Our tool performs favorably, compared to other splicing prediction methods, in context of genes linked
to ASD. SpliceScan II provided more accurate prediction of aberrant splicing events, as
documented in DBASS5 [7] and DBASS3 [8], compared to existing methods. Although the performance
of our tool predicting the effect of mutations triggering an aberrant splicing is high compared to other
methods, it could not be used as a general ab initio gene structural annotation method since the number
of false positive predicted exons is high, as could be seen in Figure 2, though the fraction of reported
false positives is comparable to what reported by other similar methods. Therefore, the most informative
use of our method would evolve screening of polymorphic variants for possible splicing alternations in
the context of known reference human gene structures. To accomplish this task we have created
companion Autism Candidate Gene Map (ACGMAP) database (http://www.meddean.luc.edu/node/375)
that contains such structures and known alternative splicing variants for candidate ASD genes.
The reason the SpliceScan II is less specific (especially for higher sensitivity values) than previous
SpliceScan tool [23] is in the nature of classification problem we address with new method. As could
be seen in Figure 4, the SpliceScan uses simple probabilistic model of scoring putative 3’ SS, where
confidence of the putative 3’ SS raises since two strong complement 5’SSs are located downstream.
However, according to [7] 3’SS would unlikely to form exon with any of the 5’ SSs located downstream
in such a way since physiologically feasible 5’SS normally avoid strong competitors nearby. Indeed,
SpliceScan scoring for both putative 5’SSs would be mediocre due to a conflict associated with their
closeness. However, this observation does not help to predict which exonic isoform would be activated.
To resolve this logical difficulty SpliceScan II makes all possible pairs of putative 3’SS and 5’SS
located no further than 400 nt apart to predict possible SSs utilization. The number of pseudo exons
formed this way outnumber the real exons by at least on order of magnitude [18], which turns in a harder
classification task than simple SSs classification. For the weak SSs the number of putative exons to be
classified is in excess of the number of weak SSs flanking them, which translates to a lower specificity
compared to simpler SSs scoring methods.
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Among the SNPs listed in dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/) as located within a gene
locus, extended with 2 kb upstream and downstream flanks, only 1% are non synonymous variants [42].
The rarity of such SNPs suggested search for other causative variants affecting protein function through
alternations in gene regulation, where disruption in splicing regulation seems a natural choice. Here we
conducted search for causative alternations under realistic assumption that not all the SNPs associated
with a disease are causative; chances are high that these SNPs were linked with causative variants
located at the same haplotype. Moreover, associated variants may have different mechanism of
compromising genome integrity such as creating missense/nonsense variants or affecting gene
transcription regulatory elements. Nevertheless, we have been able to establish a number of potentially
disease-causing splicing alternations.
Detected potentially detrimental exon score changes for disease associated SNPs are generally milder
compared to the predicted changes associated with mutations annotated in DBASS databases [7-8]. We
did not predict any disease associated SNPs causing an annotated exon to disappear, an event that would
most likely have highly detrimental consequences. Comparison to the predicted changes associated with
the same sized control groups of randomly selected SNPs indicated that disease-causing SNPs have
pronounced excess in the number of detected potentially splice-disrupting variants. Careful examination
of factors contributing to an exon score variation could lead to a plausible explanation of causative
mechanisms behind the disease associated SNPs.
The SpliceScan II is available online at http://splicescan2.lumc.edu/. The 5’GC SS sensor and the
standalone SpliceScan II program could be found at
http://www.wyomingbioinformatics.org/~achurban/.
Methods
Sequence data collection and processing
A set of 2,333,379 Tetrapoda exons extended with 205 nt flanks from adjacent introns has been obtained
as previously described in [40]. Pseudoexons, which were defined here as regions located between decoy
3’ and 5’ SSs, were extracted from intronic sequences flanked by two homology-based predicted exons
in data set of human and mouse gene structures as described in [23]. The decoy 3’ and 5’ SSs were
predicted by the Bayesian SS sensor [23]. The first and last 150 nt in every intronic sequence were
excluded to avoid statistical biases associated with exon proximal ISEs/ISSs [43]. The sum of decoy 3’
and 5’ Bayesian SS sensor scores had to exceed 0.05, where the score for each signal was on a
continuous 0 to 1 scale. The pseudoexon lengths were chosen to be longer than 5 nt and less than 400 nt,
where 99% of authentic internal exons reside in this length range [41, 44]. Flanking intronic regions of
205 nt were required on both sides of pseudo exons to estimate if any elements are associated with
pseudo SSs. Pseudo exons were also checked for uniqueness and were discarded if either flanking
regions of a pseudo exon or surrounding intronic fragments were identical to those previously processed.
Through the literature search we have collected the test set of 238 human genes previously linked to
ASD [see Additional File 3] as a sample representative collection of important human genomic regions
with potential implication in medical practice. We excluded all the extended exons corresponding to
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ASD genes from the learning set of SpliceScan II tool for the purposes of split-sample
performance testing. We constructed a test set of pre-mRNA sequences for ASD genes along with the
corresponding gene structural annotation. The set contains 4,650 known canonical 5’ and 3’ SS pairs
flanking the internal exons that need to be predicted by various methods.
Learning the model
The LOD curves were constructed for the enhancers/silencers, previously reported in [40] [see
Additional File 4], associated with the splicing signals of various strengths, an example of such
dependencies could be seen in Figure 5. We followed the assumption that the weak splicing signals are
more likely to be supported by the enhancing elements [30] and avoid silencers. In order to find LOD
characteristic we calculate 



¬
)|(Pr
)|(Prlog )(
)(
2
SS
i
SS
i
HDob
HDob
, where the quantity Prob(D|H) is called the
likelihood of the data D (in our case ISEs, ISSs, ESEs, ESSs and competing SSs) under hypothesis H,
Prob(D(i) | HSS) is a signal likelihood at location i next to a SS and Prob(D(i) | H¬SS) is a signal likelihood
at location i next to a splice-like signal.
Exon definition score is found through combining of the 5’ and 3’ SSs strengths predicted by the
Bayesian SS sensor [23] converted to LOD score, the LOD score associated with the exonic length for
given SSs strength, the LOD scores associated with the presence of the strong splicing competitor signals
in vicinity or inside of an exon defined and LOD scores associated with the enhancers/silencers. Steric
constrains and geometry of the molecular interactions dictate the optimal exonic length distribution [1,
45] where stronger SSs could sustain tighter packing of the splicing factors and therefore such exons are
shorter as could be seen in Figure 6. The LOD score for an exon of length exonSize flanked by SSs of
certain strength SSStrength '5 and SSStrength '3 are measured on a discrete scale from 1 to 5 by Bayesian SS
sensor [23]) is calculated as 
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The middle two terms in (1) are the LOD ratio associated with the posterior probability score returned by
the Bayesian sensor [23] for the 3’ and 5’ SSs. The first term in the sum (1) takes into account the
evidence provided by the enhancers/silencers and comes up with a valid posterior LOD ratio.
To resolve LOD score contribution from overlapping enhancing/silencing elements we have allocated
two sorted lists containing elements; one with positive LOD scores and another with negative. We keep
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only the elements with the highest negative LOD scores if any overlaps exist among silencers and with
the highest positive LOD score if any overlaps exist among the enhancers. Such strategy allows scoring
the overlapping elements that are antipodes in their enhancing profiles [47]. This way we can also choose
between the shorter and longer version of the predicted cis-acting elements sharing the common prefix,
relying only on elements contributing the maximum absolute LOD score.
Our Bayesian 5’GC SS sensor has been constructed in a manner similar to the canonical Bayesian 5’SS
sensor [23], which demonstrated the predictive performance superior to other SS sensor designs. To
construct the sensor, first we have collected gene structures containing 1,320 5’GC SS from homology
based annotations of human and mouse genomes (described in [23]) along with pre-mRNA frequencies
of decoy 5’GC SSs. The entire learning set of 23 Tetrapoda organisms confirmed 19,059 non-canonical
5’GC SSs. Since other organisms presented in UCSC multiple genome alignments, beyond human and
mouse, had poor genome annotations we amplified found decoy 5’GC SS scores by the factor of
44,14
320,1
059,19
= to approximate decoy counts for the 23 tetrapods. Table 3 shows first 40 top-scoring
5’GC SS posterior probabilities calculated according to the formula
)|()()|()(
)|()()|(
SSoligoPSSPSSoligoPSSP
SSoligoPSSP
oligoSSP
¬×¬+×
×
=
where P(SS) – prior probability of an oligonucleotide to be 5’GC SS, P(¬SS) – prior probability of an
oligonucleotide to be donor-like signal, P(oligo|SS) – likelihood of oligonucleotide in case of 5’GC SS,
P(oligo|¬SS) – likelihood of oligonucleotide in case of 5’GC SS-like signal.
Since the 5’GC SSs are recognized by the standard U2 spliceosome [1] and are commonly
interchangeable with the canonical 5’ SSs [36], it is reasonable to assume they share the common
context. For that reason the splicing signals predicted by the newly constructed Bayesian 5’GC SS sensor
were placed in the same probabilistic context of the normal 5’SSs, except for the different initial LOD
characteristic of the 5’GC SS sensor and additional normalization histogram to specifically normalized
score for 5’GC SSs flanked exons.
Constructing the test set
We wanted to estimate a potential implication of disease associated Single Nucleotide Polymorphisms
(SNPs) on splicing, since many such variants emerge from recently conducted association studies. A
mechanism by which these variations influence a disorder predisposition remains elusive in many cases.
We have identified 1,481 SNPs that have been previously associated with Alzheimer’s available
through AlzGene database (http://www.alzforum.org/res/com/gen/alzgene/default.asp) and the literature
sources cited at Alzheimer research forum (http://www.alzforum.org/) and the 716 SNPs that have been
previously associated with the breast cancer [48-53] [see Additional File 3]. We batch downloaded the
sequences for the SNPs from the dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/), BLASTN [54]
aligned these sequences against Ensembl genomic contig sequences obtained from EBI Alternative
Splicing Database project (http://www.ebi.ac.uk/asd/altsplice/humrel3.html), processed the results and
mapped the location of SNPs to the genomic contig sequences. For the same genomic sequences we
predicted the gene structures with BLAT [55] using the RefSeq mRNA sequences
(ftp://ftp.ncbi.nih.gov/refseq/H_sapiens/mRNA_Prot). We synchronized SpliceScan II ab initio
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splicing predictions with the homology-based annotated exons and reported changes induced by the
polymorphic variations. Sets of control SNPs were randomly selected from loci of 238 genes linked to
ASD [see Additional File 3].
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Figures
Figure 1. An example SpliceScan II output predicting an effect of mutation.
Legend: IVS2+2delC annotated in DBASS5 [7] as causing familial pulmonary arterial hypertension
[56], a single nucleotide deletion which disrupts a strong non-canonical 5’GC SS (shown as purple
circle) and causes activation of two cryptic alternatively committed canonical 5’SSs located -60 and -108
nucleotides upstream of the original SS. Here we successfully predict an effect of mutation on the
original allele shown in (A), where two alternatively used aberrant exonic isoforms activated as shown in
(B). SpliceScan II predicted 3’SSs are represented as black-and-white triangles, 5’SSs are black-
and-white circles, predicted exons are shown as blue rectangles. The more intense the color a displayed
signal, the higher its predicted strength. In (C) we show an example of SpliceScan II textual
output listing factors contributing to non-canonical GC exon score assignment shown in (A).
Figure 2. Sensitivity vs. False positive rate trajectories for various tools.
Legend: The performance of Bayesian and Maximum entropy SS sensors is compared with the
performance of tools specifically built to predict the splicing pattern independent of protein coding
context features. (A) Trajectories for 5’SS (B) Trajectories for 3’SS
Figure 3. 5’GC SS Bayesian sensor performance compared with two existing 5’GC SS sensors [12,
15] based on weight matrices.
Figure 4. Hypothetical situation of scoring putative 3’SS with SpliceScan method, where both
strong 5’SSs located downstream positively affect the confidence of 3’SS.
Figure 5. An example LOD profiles for various 5’SS ISEs/ISSs signals in vicinity of a weak 5’SS
(with discrete score 1 out of 3 possible).
Legend: Signal AAGGTAA is a core part of a strong canonical 5’SS and therefore is substantially
depleted in vicinity of true exonic boundaries as potential competitor. The distinctive bell-shaped LOD
profiles for GGGGTGGG and CGGGGGCG are from the well studied poly-G family of ISEs [31],
known to form quadruplex structures [57].
Figure 6. Exonic length distribution depends on strength of flanking SSs.
Legend: We used substantial correlation of exonic sizes and the strength of SSs to explain how certain
events change (compromise) the pattern of splicing, where 3’ and 5’ SSs strengths are in the discrete
range from 1 to 5 as measured by the Bayesian SS sensor [23]. (A) Histogram of the internal exon length
distribution. (B) The exonic length distribution histograms were interpolated with the mixture of Beta
distributions fit with the Expectation Maximization (EM) as discussed in [23].
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Tables
Table 1. Tools accuracy predicting the aberrant splicing events.
Databases
DBASS5 [7] DBASS3 [8]Prediction method
Correct Incorrect Accuracy Correct Incorrect Accuracy
ExonScan [29] 42 320 11.6% 8 117 6.4%
GenScan [20] 52 310 14.36% 21 104 16.8%
SpliceScan II 100 262 27.62% 40 85 32%
Interpretation of counts reported in the table could be found in [see Additional File 1].
Table 2. Number of predicted splicing events induced by the same number of disease associated and
control SNPs randomly selected from the loci of 238 genes linked to ASD.
997 SNPs 539 SNPs
Type of event Alzheimer’s
associated Control Ratio
Breast cancer
associated Control Ratio
Predicted exon
corresponding to an
annotated exon disappears
0 2 0 0 0 -
Predicted exon
corresponding to an
annotated exon changes a
score
43 12 3.58 11 2 5.5
Predicted exon sharing a SS
with an annotated exon
changes a score
242 78 3.10 59 29 2.03
Predicted exon sharing a SS
with an annotated exon
disappears
23 4 5.75 6 1 6.00
New predicted cryptic exon
is created sharing a SS with
with an annotated exon
26 9 2.89 5 1 5.00
Predicted exon disappears 50 49 1.02 30 17 1.76
New predicted cryptic exon
is created 50 46 1.08 24 25 0.96
Legend: Comparison is made in context of known annotated reference exons. Not all the originally
available SNPs associated with a disorder mapped to loci of protein coding genes, therefore number of
SNPs reported here is lower than originally obtained [see Subsection Constructing the test set].
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Table 3. Frequencies of oligonucleotides playing role of 5’GC SSs versus frequency of decoy 5’GC SS-
like oligonucleotides in pre-mRNA sequences recordered for tetrapoda organisms.
Signal Counted as trueSS in Vertebrates
Counted as decoy
SS in Vertebrates Bayesian posterior Normalized
CAGGCAAGT 3263 36400 0.082 0.914
AAGGCAAGT 3246 41193 0.073 0.744
GAGGCAAGT 1898 35375 0.051 0.609
ACGGCAAGT 143 4519 0.031 0.555
AAGGCGAGT 199 6570 0.029 0.546
CAGGCGAGT 231 8750 0.026 0.535
ATGGCAAGT 580 30928 0.018 0.514
TCGGCAAGT 64 3971 0.016 0.497
GAGGCGAGT 141 9746 0.014 0.491
CCGGCAAGT 62 4534 0.013 0.486
AAGGCAAGC 415 36154 0.011 0.474
TAGGCAAGT 398 34927 0.011 0.452
CGGGCAAGT 64 5963 0.011 0.440
AAGGCACGT 92 10006 0.009 0.436
CTGGCAAGT 304 34884 0.009 0.426
AAGGCAAGG 475 54694 0.009 0.405
AAGGCAAGA 517 61104 0.008 0.379
CAGGCAAGA 365 55964 0.006 0.356
CAGGCAAGG 351 55387 0.006 0.337
CAGGCAAGC 275 44919 0.006 0.321
GAGGCACGT 51 9371 0.005 0.312
AGGGCAAGT 175 32213 0.005 0.306
TTGGCAAGT 188 36674 0.005 0.297
AACGCAAGT 19 3870 0.005 0.291
GCGGCAAGT 20 4303 0.005 0.290
GAGGCAAGC 166 37252 0.004 0.285
CGCGCAAGC 5 1155 0.004 0.281
AAGGCAGGT 292 75658 0.004 0.273
CCGGCACGT 9 2455 0.004 0.265
CAGGCACGT 122 35158 0.003 0.262
CCGGCGAGT 7 2036 0.003 0.258
GAGGCATGT 114 33194 0.003 0.255
TCGGCGAGT 4 1184 0.003 0.252
CAGGCAGGT 271 81896 0.003 0.245
TAGGCGAGT 12 3855 0.003 0.238
ATGGCGAGT 18 5790 0.003 0.237
AAAGCAAGT 209 67530 0.003 0.231
ACGGCACGT 5 1617 0.003 0.225
AAGGCATGT 174 60195 0.003 0.220
AAGGCGCGT 5 1733 0.003 0.216
Here prior probability for 5’GC SS is 51016.5)( −×=SSP .
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Additional files
Additional file 1
File format: XLS
Title: Report and analysis of mutations causing aberrant splicing events reported in DBASS5 [7] and
DBASS3 [8] databases.
Description: Prediction accuracy for aberrant splicing events triggered by mutations is reported for
SpliceScan II, ExonScan [29] and GenScan [20] tools.
Additional file 2
File format: DOC
Title: Predicted splicing variations caused by SNPs previously associated with Alzheimer’s and the
breast cancer.
Description: SNPs previously associated with Alzheimer’s and breast cancer predicted to change the
pattern of splicing.
Additional file 3
File format: XLS
Title: Genes linked to ASD, SNPs previously associated with Alzheimer’s and breast cancer and control
SNPs randomly picked from loci of genes associated with ASD.
Description: SNPs previously associated with Alzheimer’s and breast cancer and genes linked to ASD
were collected through literature search.
Additional file 4
File format: PDF
Title: Splicing regulatory elements reported in [40] and their statistical significance.
Description: Repertoire of exonic and intronic splicing enhancer/silencer elements used in building of
SpliceScan II tool.
A B
GC EXON LOCATED AT 379 - 549 HAS LOD SCORE -9.01 NORMALIZED 0.52
* ACCEPTOR CTTTATTTCCTTTATTTTAGCTT LOCATED AT 379
OF STRENGTH 0.54 WITH LOD SCORE -2.91
* GC DONOR AAGGCAAGT LOCATED AT 549
OF STRENGTH 0.74 WITH LOD SCORE -3.89
* EXON OF SIZE 171 WITH LOD SCORE 0.62
+ ACCEPTOR ESE/ESS TAGGT
LOCATED AT 439 - 443 WITH LOD SCORE -2.82
C
3'SS ESE/ESS 
TAGGT, LOD=-2.82
5'GC SS AAGGCAAGT, 
STRENGTH=0.74, LOD=-3.89
3' SS CTTTATTTCCTTTATTTTAGCTT, 
STRENGTH=0.54, LOD=-2.91
Predicted exon of size 171, LOD=-9.01,
STRENGTH = 0.52
5' SS TAGGTGAGA, 
STRENGTH=0.22, LOD=-4.28
5' SS AAGGTAGCA, 
STRENGTH=0.14, LOD=-5.30
3' SS CTTTATTTCCTTTATTTTAGCTT, 
STRENGTH=0.54, LOD=-2.91
5'SS ISE/ISS AGGTA, 
LOD=-2.26
3'SS ESE/ESS 
TAGGT, LOD=-2.82
5'SS ESE/ESS AGGTGAG, 
LOD=-3.80
Predicted exon of size 111, LOD=-10.68,
STRENGTH = 0.18
Predicted exon of size 63, LOD=-9.04,
STRENGTH = 0.28
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